Verasonics Expands Leadership, Announcing Additions to the Executive Team and New Focus in Commercial Sales

2022-12-07
高管变更
KIRKLAND, Wash.--(BUSINESS WIRE)--Verasonics, Inc., the leader in research ultrasound, today announced that it has expanded its leadership team with the appointment of Don Christopher, Ph.D. as Chief Technology Officer (CTO) and Stacy Douthitt as Chief Business Officer (CBO). In addition, the company has added Alex Exposito as Director of Commercial Sales. Ken Linkhart, Verasonics’ former CTO, is continuing with Verasonics as the organization’s first Technical Fellow.
'I am pleased to welcome Don, Stacy and Alex to the Verasonics Team'
“I am pleased to welcome Don, Stacy and Alex to the Verasonics Team,” said Jon K. Daigle, President and Chief Executive Officer at Verasonics. “Their collective and broad expertise across technology, product development, and sales and marketing significantly strengthen our core capabilities. As we look to the future, we are focused on advancing the features and functionality of the Vantage™ Research Ultrasound System to continue to address the needs of our customers while further accelerating sales growth in academic and commercial entities. With these additions and changes to our team, we will continue to fuel our pursuit of these objectives and extend our leadership position in the research ultrasound arena.”
Dr. Christopher joined the Verasonics’ team in April 2021 as Vice President of Engineering. He came to Verasonics with 35 years’ experience in ultrasound product development and research leadership roles at renown medical imaging commercial companies including ATL Ultrasound, Philips Medical Systems, Kona Medical, FUJIFILM SonoSite, and Siemens Healthineers. In addition to his role as CTO, he is also responsible for engineering, operations, quality and regulatory. Dr. Christopher received his Master of Science and Doctorate in Medical Biophysics in Medical Imaging from the University of Toronto.
Ms. Douthitt is a senior marketing leader with 30 years of demonstrated results in commercial strategy and global marketing for medical device and life science firms. Prior to Verasonics, she held leadership positions at several MedTech companies ranging from start-up to Fortune 500. She has helped to lead four start-ups to successful exits. Ms. Douthitt is also responsible for customer success, product marketing & communications, as well as strategic marketing & alliances. She holds a B.A. in Marketing from the University of Washington, and an M.B.A. from the University of Phoenix.
Mr. Exposito is a bilingual healthcare sales leader with over 25 years’ experience in driving the growth and development of innovative medical and research technologies used to improve healthcare. Prior to Verasonics, he was Vice President of Sales at EchoLight Medical, a developer of bone densitometry solutions. Mr. Exposito has also held clinical, sales and executive positions at leading ultrasound companies and is a diagnostic medical sonographer. He holds B.S. in Administration with a Specialization in Health Services and is an M.B.A. Candidate.
Verasonics is a privately held company founded in 2001, with headquarters in Kirkland, Washington, USA. Verasonics is the leader in research ultrasound and is focused on providing researchers and developers with the most advanced and flexible tools enabling them to develop new algorithms and products used in biomedical ultrasound, materials science, earth sciences, and the physics of acoustics and ultrasonics. Verasonics also licenses its technology to companies for use in their commercial products. Researchers in nearly 40 countries across North and South America, Europe, Asia and Oceania routinely use Verasonics product solutions to advance the art and science of ultrasound through their own research efforts.
Learn more by visiting the Verasonics website or following us on LinkedIn and Twitter.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。